About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT04888910

Novel Inflammatory Markers in Different Phenotypes of Severe Asthma

Asthma is a highly prevalent chronic airway inflammatory disease characterized by airway hyper-responsiveness, reversible airflow obstruction and increased mucus secretion, involving large and small a...

Lead sponsor: University of Pisa•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Ilaria Puxeddu, MD, PhD

CONTACT

+393394740912 ilaria.puxeddu@unipi.it

Sponsors

Lead Sponsor

University of Pisa

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Male or female
•age (18-65 years)
•Diagnosis of severe asthma according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) definition, with and without nasal symptoms
•normal pulmonary function post-therapy (FEV1 post-bronchodilation: greater than 80% of the predicted value, with FEV1/ vital capacity (VC) \> 88-89% - for males and females, respectively - of the predicted value)
•non reversible chronic airflow limitation (FEV1 post-bronchodilation: lower than 70% of the predicted value, with FEV1/VC \< 88-89% of the predicted value)
•Signing of the informed consent

Exclusion Criteria

•Referred Pregnancy
•Use of therapy with beta-blockers
•Smoking (current or within the previous 3 months)
•Negation to participate to the study
•Current upper and lower airways infectious diseases
•Current systemic infectious diseases

Related studies

RECRUITINGPhase 2

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

NCT07301736 · Asthma

RECRUITINGPhase 3

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995 · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Remote Anxiety Management for ICS-resistant Asthma Study

NCT06732141 · Asthma

RECRUITINGPhase 2

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263 · Asthma

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

NCT07245576 · Asthma, COPD

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 21, 2021Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment80

Start dateMar 2021

Last updatedMay 21, 2021

Condition

Asthma Nasal Polyps

Locations shown

Pisa University

Pisa, Tuscany

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2021Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions